2023 ACS - LANA lymphedema summit forward momentum; future steps in lymphedema management.

IF 2.8 4区医学 Q2 ONCOLOGY Medical Oncology Pub Date : 2024-08-19 DOI:10.1007/s12032-024-02476-5

Elizabeth Campione, David Doubblestein

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2023 ACS - LANA 淋巴水肿峰会前进的动力；淋巴水肿管理的未来步骤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.

期刊最新文献

ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma. The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology. CAP superfamily proteins in human: a new target for cancer therapy. Letter to the editor on "Targeted gene therapy for cancer: the impact of microRNA multipotentiality". Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.